Leonardo Rojas, Guillermo Villacampa, Daniel Shao Weng Tan, Oscar Arrieta, Jairo Zuluaga, Andrés Felipe Cardona
{"title":"空气污染和egfr突变流行的世界地图。","authors":"Leonardo Rojas, Guillermo Villacampa, Daniel Shao Weng Tan, Oscar Arrieta, Jairo Zuluaga, Andrés Felipe Cardona","doi":"10.1007/s12094-025-04039-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The objective of this study was to analyze the association between mean PM<sub>2.5</sub> levels from 2000 to 2020 and the prevalence of epidermal growth factor receptor (EGFR) mutations worldwide.</p><p><strong>Patients and methods: </strong>We fitted linear regression models weighted by the total number of non-small cell lung cancer (NSCLC) to estimate the association strength. Adjusted R<sup>2</sup> values were calculated, with values closer to 1 indicating a stronger association. Data from sixty-nine countries were available. PM<sub>2.5</sub> data for 2015‒2020 were obtained from the Organisation for Economic Co-operation and Development database ( https://stats.oecd.org/ ). Mean PM<sub>2.5</sub> levels, EGFR mutation prevalence data, and total NSCLC cases were acquired from published literature and national cancer registries.</p><p><strong>Results: </strong>The association between PM<sub>2.5</sub> levels and EGFR-mutant prevalence ranged between moderate and weak (R<sup>2</sup> = 0.34, 95% Confidence interval [CI] 0.02‒0.67). The association further weakened (R<sup>2</sup> < 0.15 in all comparisons) when stratified by area (European, Asian, or Latin American). Although certain countries had high air pollution and EGFR-mutant lung cancer prevalence (China: PM<sub>2.5</sub>, 46.9% and 45.7%, respectively), the association was inconsistent.</p><p><strong>Conclusions: </strong>The discrepancy between PM<sub>2.5</sub> levels and the prevalence of EGFR-mutant lung cancer could be attributed to differences in access to lung cancer genomic profiling, potential over- or underestimation of EGFR-mutant prevalence, non-homogeneous PM<sub>2.5</sub> levels within countries, inclusion of all patients with lung cancer regardless of smoking patterns, and other factors, such as genomic background and ancestry. These factors should be considered as potential limitations in directly associating PM<sub>2.5</sub> with EGFR-mutated lung cancer development.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A world map of air pollution and EGFR-mutant prevalence.\",\"authors\":\"Leonardo Rojas, Guillermo Villacampa, Daniel Shao Weng Tan, Oscar Arrieta, Jairo Zuluaga, Andrés Felipe Cardona\",\"doi\":\"10.1007/s12094-025-04039-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>The objective of this study was to analyze the association between mean PM<sub>2.5</sub> levels from 2000 to 2020 and the prevalence of epidermal growth factor receptor (EGFR) mutations worldwide.</p><p><strong>Patients and methods: </strong>We fitted linear regression models weighted by the total number of non-small cell lung cancer (NSCLC) to estimate the association strength. Adjusted R<sup>2</sup> values were calculated, with values closer to 1 indicating a stronger association. Data from sixty-nine countries were available. PM<sub>2.5</sub> data for 2015‒2020 were obtained from the Organisation for Economic Co-operation and Development database ( https://stats.oecd.org/ ). Mean PM<sub>2.5</sub> levels, EGFR mutation prevalence data, and total NSCLC cases were acquired from published literature and national cancer registries.</p><p><strong>Results: </strong>The association between PM<sub>2.5</sub> levels and EGFR-mutant prevalence ranged between moderate and weak (R<sup>2</sup> = 0.34, 95% Confidence interval [CI] 0.02‒0.67). The association further weakened (R<sup>2</sup> < 0.15 in all comparisons) when stratified by area (European, Asian, or Latin American). Although certain countries had high air pollution and EGFR-mutant lung cancer prevalence (China: PM<sub>2.5</sub>, 46.9% and 45.7%, respectively), the association was inconsistent.</p><p><strong>Conclusions: </strong>The discrepancy between PM<sub>2.5</sub> levels and the prevalence of EGFR-mutant lung cancer could be attributed to differences in access to lung cancer genomic profiling, potential over- or underestimation of EGFR-mutant prevalence, non-homogeneous PM<sub>2.5</sub> levels within countries, inclusion of all patients with lung cancer regardless of smoking patterns, and other factors, such as genomic background and ancestry. These factors should be considered as potential limitations in directly associating PM<sub>2.5</sub> with EGFR-mutated lung cancer development.</p>\",\"PeriodicalId\":50685,\"journal\":{\"name\":\"Clinical & Translational Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical & Translational Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12094-025-04039-0\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-025-04039-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
A world map of air pollution and EGFR-mutant prevalence.
Purpose: The objective of this study was to analyze the association between mean PM2.5 levels from 2000 to 2020 and the prevalence of epidermal growth factor receptor (EGFR) mutations worldwide.
Patients and methods: We fitted linear regression models weighted by the total number of non-small cell lung cancer (NSCLC) to estimate the association strength. Adjusted R2 values were calculated, with values closer to 1 indicating a stronger association. Data from sixty-nine countries were available. PM2.5 data for 2015‒2020 were obtained from the Organisation for Economic Co-operation and Development database ( https://stats.oecd.org/ ). Mean PM2.5 levels, EGFR mutation prevalence data, and total NSCLC cases were acquired from published literature and national cancer registries.
Results: The association between PM2.5 levels and EGFR-mutant prevalence ranged between moderate and weak (R2 = 0.34, 95% Confidence interval [CI] 0.02‒0.67). The association further weakened (R2 < 0.15 in all comparisons) when stratified by area (European, Asian, or Latin American). Although certain countries had high air pollution and EGFR-mutant lung cancer prevalence (China: PM2.5, 46.9% and 45.7%, respectively), the association was inconsistent.
Conclusions: The discrepancy between PM2.5 levels and the prevalence of EGFR-mutant lung cancer could be attributed to differences in access to lung cancer genomic profiling, potential over- or underestimation of EGFR-mutant prevalence, non-homogeneous PM2.5 levels within countries, inclusion of all patients with lung cancer regardless of smoking patterns, and other factors, such as genomic background and ancestry. These factors should be considered as potential limitations in directly associating PM2.5 with EGFR-mutated lung cancer development.
期刊介绍:
Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.